| |
|
|
|
Nymox Pharm Corp  
|
|
2.41 0.04 (0.02%) |
10-19 11:40 |
|
Open: |
2.36 |
Pre close: |
2.37 |
Target:
|
3.13 
|
|
High: |
2.48 |
Low: |
2.35 |
Resistance:
|
2.68
3.13
|
|
Volume: |
28,796 |
Market Cap: |
189M |
Support:
|
2.30
2.07
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.34
|
MACD |
MACD(12,26):
|
-0.06 |
|
MA(20): |
2.38 |
Signal(12,26,9): |
-0.08 |
|
MA(100): |
3.03  |
Stochastic Oscillator |
%K(14,3):
|
51.37 |
|
MA(250): |
2.74 |
%D(3): |
43.72 |
|
Average Volume(K) |
3-Month: |
15106
|
52-Week |
High:
|
4.79 |
|
10-Days: |
11132 |
Low: |
1.66 |
|
RSI |
RSI(14):
|
50.50 |
Change(%): |
32.8 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.152 |
Return on Equity (ttm) |
-329.3 |
Shares Out. (M) |
76.36 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-127.3 |
Shares Float (M) |
41.10 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
39.94 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
2.55 |
|
Forward EPS |
-0.180 |
Gross Profit (p.s.) |
0.001 |
Shares Short (K) |
3830 |
|
Book Value (p.s.) |
-0.010 |
EBITDA (p.s.) |
-0.134 |
P/E |
-15.99 |
|
Sales Per Share |
0.001 |
Qtrly Earnings Growth |
0.00 |
P/BV |
-243.00 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-8.04 |
P/S |
2613.45 |
|
Operating Margin |
-15166.20 |
Levered Free Cash Flow
(M) |
-3.86 |
P/CF |
-23.08 |
|
|
|
|
|
|
